Northern Californias bay area, which includes San Francisco, San Mateo, Santa Clara, Napa, and Marin County, is home to some of the most well-established biopharma companies. The atmosphere is chill, the mood relaxed unless you happen to work for one of these scientific innovators where drive and determination are required to meet the mission.
The Biotech Bay region is home to 3,418 life sciences companies, and 96,574 employees making an average of $151,076. Focuses and technologies range from cell and gene therapy to precision medicine and polymer chemistry, targeting rare diseases along with more pervasive killers. And these seven companies just happen to have a wealth of job openings right now.
Gilead Sciences Inc.
Nestled in Foster City, a small hamlet in San Mateo County, Gilead Sciences is well-known for its achievements in viral diseases, most notably human immunodeficiency virus (HIV).
With a mission of developing novel therapeutics for life-threatening illnesses with unmet medical need, Gilead has an impressive list of FDA-approved medicines. These include Veklury, better known as the COVID-19 therapy, remdesivir, Biktarvy, a single tablet HIV regimen, and Yescarta, a chimeric antigen receptor T cell (CAR-T) drug acquired along with Kite Pharma in 2017.
In 2020, Gilead employed approximately 13,600 individuals. This was an increase of around 2000 (15.25%) from 2019, and the company is growing again.
For those passionate about global access to cancer medicines, Gilead is hiring a Director, Value & Access Strategy Oncology. The successful applicant will have at least 12 years of biopharma experience in market access-related activities bonus points if this is on a regional or country basis. For the more statistically-inclined, Gilead is looking for a Sr. Manager, Biostatistics Oncology.
With well over 300 positions available, opportunities abound to join this Biotech Bay leader.
BioMarin Pharmaceutical Inc.
Established in 1997, San Rafael-based BioMarin specializes in super-rare diseases. BioMarin is targeting cures for diseases like inherited metabolic disorder, Phenylketonuria (PKU), and the rapidly progressing pediatric brain disorder, late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). The company also has a strong presence in hemophilia.
With six commercially approved drugs and a market cap of $15.4 billion, BioMarin was cited by Zacks Equity Research as one of four potential biotech takeover targets for 2021. Whether this will be the case, only time will tell, but BioMarin is getting even bigger, with nearly 200 open posts, including:
Associate Director, Global Brand Management - Strategy and Operations. Anyone wanting to make this strategic career move will need to have a minimum of 7 years of pharmaceutical/biotech industry experience.
Senior Associate - Regulatory Affairs. The successful candidate will possess superior decision-making and problem-solving skills and have a tendency to thrive in a cross-functional business environment. A degree in health or life sciences is required; Ph.D. preferred.
Category Manager, Single Use Technology. This job is for those passionate about supply chain operations, with 5-plus years of strategic procurement experience and 3-plus years in the biotech/life sciences industry. BioMarin would prefer someone with an MBA or MS, and a C.P.M.
Arcus Biosciences, Inc.
Founded in 2015, Arcus Biosciences is combining precision therapeutic strategies in an effort to defeat cancers that have thus far eluded medicine. Arcus has clearly been busy over the past six years, with 13 programs in clinical development and five more coming down the discovery pipeline. Targets include a wide range of cancers, including non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer, and colorectal cancer.
Those seeking a position within this unique biopharma company should check out some of the 90-plus jobs currently available. Here are just a couple:
Bioanalytical Scientist. Arcus is actively recruiting a scientist for its Drug Metabolism and Pharmacokinetics (DMPK) department. Interested candidates with a Ph.D. in pharmaceutical sciences or related disciplines should apply.
Principal Investigator/Clinical Biomarkers Translational Science. Arcus is seeking a candidate with expertise in the development, execution, and oversight of biomarker plans for oncology assets.
Associate Director, Clinical Supply. The winner of this position will play a role in all of Arcuss clinical development problems. The desired applicant will have 7-plus years of relevant experience and a Masters degree.
Global Blood Therapeutics
Global Blood Therapeutics (GBT) is comprised of nearly 400 people driven by the mission of delivering life-changing treatments for those with sickle cell disease (SCD) and other severe blood disorders. In late 2019, the FDA approved GBTs oxbryta (voxelotor) as the first treatment to directly inhibit sickle hemoglobin polymerization, the root cause of SCD. Other investigative medicines include a potential treatment to limit the frequency of vaso-occlusive crises (VOCs) and multiple other shots on goal for SCD.
Located on Oyster Point Boulevard in South San Francisco, GBT is looking for new talent to fill more than 80 positions, including:
Director, Clinical Operations. GBT is open to hiring the right person to work remotely from anywhere in the U.S. for this prime leadership position.
Associate Director, Pharmacovigilance Operations. Another remote opportunity for a vigilant leader with 10 or more years of pharmacovigilance experience in an operational and compliance position.
Nektar Therapeutics
San Francisco-based Nektar Therapeutics is focused on curing cancer and autoimmune disease using polymer chemistry, a unique approach to drug design that uses optimized pharmacology to create new molecular entities.
Nektar is leveraging this technology to develop five clinical-stage investigational drugs with partners Bristol Myers Squibb, Biogen, Eli Lilly & Co., and Vaccibody. The companys lead immuno-oncology candidate, bempegaldesleukin, is an IL-2 pathway agonist designed to stimulate the immune system to fight cancer. It is currently being tested in phase III for a number of indications in combination with BMSs OPDIVO. In February, Nektar inked a co-development deal with SFJ Pharmaceuticals to advance bempegaldesleukin in head and neck cancer.
With all of these programs, it is no wonder Nektar is sourcing new talent for more than 50 positions. Here are just a couple.
Clinical Trial Manager. If any (or all) of the above programs appeal, this role might be the right fit. The successful applicant will have eight years of pharmaceutical development experience, with at least two years overseeing trials.
Principal Medical Science Liaison (MSL)-Northeast. A remote opportunity for a creative, technical, and scientifically-minded individual hailing from the Northeast.
Sangamo Therapeutics, Inc.
This genomic medicine company touches on many of biotechs hottest areas including gene therapy, cell therapy, and in vivo genome editing. Sangamos diverse preclinical and clinical-stage pipeline is aimed at solving life-limiting diseases like Hemophilia A, Amyotrophic lateral sclerosis (ALS), Phenylketonuria (PKU), and Fabry disease.
In July 2020, Sangamo entered into a collaboration with Novartis to develop and commercialize gene regulation therapies for three neurodevelopment targets, including autism spectrum disorder. The agreement leverages Sangamos proprietary genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), which aims to upregulate the expression of genes in these disorders.
Anyone wishing to participate in this mission should check out one of Sangamos available positions. A Research Associate III/IV job is one of many associate-level opportunities currently on the board. There are also openings for a few scientist-level positions, including a Research Scientist, Molecular Biology.
Sana Biotechnology
This cell and gene therapy hybrid is developing its cell engineering platform to deliver any payload to any cell in a specific, predictable and repeatable way. Sana is aiming this technology at a wide range of oncologic, genetic, CNS, and cardiovascular targets in a currently all preclinical pipeline.
Sana has been vocal about its culture of inclusion, diversity and equity (IDE), which leadership believes is paramount to its patient-centric culture. By tapping Head of Development Operations, Farah Anwar, as its IDE leader, Sana has ensured that a senior executive is privy to the people dynamics as well the medical ones.
Sana is currently looking to bring on board a Head of Facilities to spearhead its capital project master plan, a Principal Scientist, Genomics Core to advance this key technology, and a Cloud Systems Administrator to oversee the design.
Here is the original post:
Biotech Bay is Rich With Opportunity in the Industry's Hottest Spaces - BioSpace
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]